



# CLINICAL CANCER GENOMICS COMMUNITY OF PRACTICE

CITY OF HOPE DIVISION OF CLINICAL CANCER GENOMICS


This recording is provided for review purposes only and viewing *does not* substitute attendance.

Due to HIPAA, please **DO NOT** attempt to distribute this document or the corresponding recording.

## \*CHAT LOG TIMECODES MAY NOT ALIGN WITH RECORDING\*

00:20:21 Diane Stoller: Is there a CME code?  
00:20:41 Clinical Cancer Genetics: CME code for this session: KOGMAY  
00:21:16 Erica Kessler: Hi! Can someone send the code please?  
00:21:30 Clinical Cancer Genetics: CME code for this session: KOGMAY  
00:24:00 Bita Nehoray (she/her): Some pedigree reminders for our current IC cohort, placing a number within a circle/square/diamond indicates the # of people, not age. Age is typically listed under the individual in subcomments.  
00:24:28 Tara Lien: What is the number we text the code to please?  
00:24:44 Bita Nehoray (she/her): Also, encourage shading in for diagnoses to more easily assess patterns  
00:25:07 City of Hope - PopSci Conference Room: Reminder for individuals in the current IC cohort, you do not need to text the CME code in for credit  
00:25:35 Clinical Cancer Genetics: CME text-in number: (626) 314-7448 (IC participants do not need to text in)  
00:26:41 Bita Nehoray (she/her): Agree, interesting case!  
00:26:53 Michelle Weaver Knowles: Yippee for panel testing!  
00:26:58 Jeffrey Weitzel: Does the 78 yo have her ovaries?  
00:27:09 City of Hope - PopSci Conference Room: No she had BSO  
00:27:26 Dara McKinley FNP-C AGN-BC: why did she see onc?  
00:27:45 gina shay-zapien: Can you tell us more about the MITF mutation?  
00:28:23 Jeffrey Weitzel: BSO was the most important intervention. The CARRIERS project provides population-based risk estimates (BC risk only ~50% absent FHx  
00:29:09 Robbin Palmer: Fallopian tubes gone, too?  
00:29:53 City of Hope - PopSci Conference Room: I think it's a little difficult to tell the cancers without shading, but there are some breast cancers in the family  
00:30:26 Cindy Snyder DNP, ACGN, FNP-C. CBCN: Does the 78 y/o proband's daughter have children?  
00:30:42 Tami Hudson : No children  
00:30:47 Dara McKinley FNP-C AGN-BC: thank you for pointing that out JW--sometimes it is hard to know in the older population  
00:32:34 Denise Jeffery: In an earlier working group MITF was discussed. At that time Dr Slavin had recommended screening for renal cancer. Would that be recommended for these individuals?  
00:33:11 City of Hope - PopSci Conference Room: We have done baseline screening for RCC but there are no guidelines  
00:33:22 City of Hope - PopSci Conference Room: No defined risk # yet and no screening guidelines  
00:33:30 Constance Murphy: screening how? MRI versus ultrasound?  
00:33:56 City of Hope - PopSci Conference Room: It has been associated with clear cell RCC so ultrasound should be able to detect that  
00:34:09 City of Hope - PopSci Conference Room: We think about MRI/CT when it comes to papillary type RCC in which US is not as good

00:35:10 Tom Lin, MD: MITF plus BRCA2 is riskier than MITF alone?  
00:35:43 Steve Gruber: Yes...additive for sure. Don't know if it is more than additive.  
00:35:59 Steve Gruber: ...for melanoma  
00:36:06 Tom Lin, MD: MITF alone is riskier than MITF plus BRCA1?  
00:36:26 Tonia Markel: Why was panel testing done on the children instead of family variant testing? Is this generally the recommendation?  
00:37:36 Steve Gruber: I almost always recommend panel testing in at-risk family members, not family variant testing.  
00:37:54 Lauren Gima (she/her): Either option could be appropriate, but we typically offer panel testing to all in our practice  
00:37:56 Dara McKinley FNP-C AGN-BC: Rachele can you repeat the MITF AR syndrome? I have not been counseling on that  
00:38:02 Lauren Gima (she/her): COMMAD syndrome  
00:38:40 Dara McKinley FNP-C AGN-BC: ok--not in ambry reports that I know of  
00:38:46 COH - Sandra Dreike: coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness  
00:38:56 Dara McKinley FNP-C AGN-BC: thank you  
00:39:00 Clinical Cancer Genetics: CME code for this session: KOGMAY  
00:39:26 Cindy Snyder DNP, ACGN, FNP-C. CBCN: What is the incidence for COMMAD?  
00:40:56 Tom Lin, MD: Earlier, it was mentioned that BRCA1 can have ressesive condition. Can you elaborate more?  
00:41:01 Erica Kessler: Does the MyRisk discuss COMMAD? I don't remember seeing  
00:41:22 Christine Strub: In Switzerland testing for a known Mutation is About 400 CHF and Panel testing is 4000 CHF.  
00:41:22 Kathleen Mott: :also PGM had pancreatic cancer  
00:41:50 gina shay-zapien: are those MITF mutations in the son and daughter different or just named differently because of the different labs?  
00:41:54 Lauren Gima (she/her): COMMAD syndrome is rare. I think still more case report level, so no incidence rates known currently  
00:42:53 COH - Sandra Dreike: @gina - the MITF mutations are the same, the notation used by the labs is just slightly different abbreviations for the amino acids  
00:43:08 City of Hope - PopSci Conference Room: Kathy is my 2nd mom  
00:43:26 City of Hope - PopSci Conference Room: 😊  
00:43:36 COH - Kathleen Blazer: And proud of it!  
00:44:12 Clinical Cancer Genetics: Reminder: This is our last Working Group session of 2022. The next session will be on January 4th, 2023.  
00:44:15 gina shay-zapien: thanks! I remember that from one of the first lectures now!  
00:44:18 Dara McKinley FNP-C AGN-BC: I think there is only one MITF mutation that is onpanel correct?  
00:44:20 Bitá Nehoray (she/her): [https://molbiol-tools.ca/Amino\\_acid\\_abbreviations.htm](https://molbiol-tools.ca/Amino_acid_abbreviations.htm)  
00:44:40 Bitá Nehoray (she/her): Some labs do full gene MITF, others may only look at E318K  
00:44:59 Dara McKinley FNP-C AGN-BC: got it 😊  
00:46:17 Lauren Gima (she/her): Shading for different cancers and legends are always our friend on pedigrees, too!  
00:47:11 Clinical Cancer Genetics: Reminder: This is our last Working Group session of 2022. The next session will be on January 4th, 2023.  
00:47:24 Clinical Cancer Genetics: CME code for this session: KOGMAY  
00:47:33 Robbin Palmer: Fallopina tubes?  
00:47:49 Cindy Snyder DNP, ACGN, FNP-C. CBCN: I would be curious to know how Tami's program handle VUSs.  
00:47:52 Dara McKinley FNP-C AGN-BC: Happy holidays to all of you!!! 🎄  
00:48:37 Robbin Palmer: THX  
00:48:42 City of Hope - PopSci Conference Room: 🎅  
00:48:48 Tom Lin, MD: It is nothing to do with the case. If the patient has blood malignancy being treated, and needs gremline testing, why needs to skin punch biopsy for fibroblast, not saliva or blood?

00:49:00 City of Hope - PopSci Conference Room: 

00:49:10 COH - Sandra Dreike: Keep in mind with MITF the mutation found in this family is associated with melanoma and not the recessive conditions

00:49:33 Dara McKinley FNP-C AGN-BC: @Sandra is the common MITF mutation associated?

00:49:33 City of Hope - PopSci Conference Room: Tom stay tuned! There is a lecture to come about this closer to the end of the course RE heme malign and skin punch bx

00:49:36 Cindy Snyder DNP, ACGN, FNP-C. CBCN: And who is the ordering provider for the tests done?

00:50:22 Dara McKinley FNP-C AGN-BC: We have a nurse check in with VUS results very 3 years. She checks CLINVAR and gets any updates from family

00:50:40 Bitá Nehoray (she/her): Also, NIH has a genomeconnect program

00:50:48 Bitá Nehoray (she/her): That patients can participate in

00:51:09 Bitá Nehoray (she/her): <https://www.genomeconnect.org/en/>

00:53:36 gina shay-zapien: base theorem?

00:53:53 Elyssa Zukin: Bayes

00:53:56 Cynthia Hellman-Wylie: Baye's


00:54:03 Tom Lin, MD: If we still have some time, can I ask a case that I just discussed at breast tumor board an hour ago. The oncologist had different opinion from genetic counselor.

00:54:09 COH - Sandra Dreike: Bayesian analysis is the full term

00:54:17 Elyssa Zukin: Thanks Sandra!

00:55:13 Dara McKinley FNP-C AGN-BC: thank you--I was sweating a bit Rachelle

00:55:19 Erica Kessler: Saaaame

00:55:24 Dara McKinley FNP-C AGN-BC: 

00:56:18 Jeffrey Weitzel: Even better, would be the ability to do a "traceback" approach to sequence the archival OC patient tumor.

00:56:26 City of Hope - PopSci Conference Room: SORRY!!!! HUGS!!

00:56:30 City of Hope - PopSci Conference Room: -Rach

00:56:38 Dara McKinley FNP-C AGN-BC: perfect! No worries

00:58:36 Steve Gruber: Bayes theorem is right in the wheelhouse of genetic counselors and geneticists...you use prior information to calculate the posterior probability that someone is a carrier. Fun to do, actually, and plenty of software to make it easy to calculate. BRCAPro can do the trick.

00:59:37 Steve Gruber: Dr. Weitzel is EXACTLY right. Great point about tumor block testing. Even more informative, when available.

01:00:40 Dara McKinley FNP-C AGN-BC: I want to work with YOU GUYS--so interesting!

01:01:19 Bitá Nehoray (she/her): Yes

01:01:37 Bitá Nehoray (she/her): Which is why it's just as important to include unaffected individuals in Tyrer Cuzick

01:02:52 Clinical Cancer Genetics: CME code for this session: KOGMAY

01:05:04 City of Hope - PopSci Conference Room: Do we have the panel?

01:05:08 City of Hope - PopSci Conference Room: To know what was included?

01:05:33 City of Hope - PopSci Conference Room: I would try to get a copy of the test report

01:05:34 Cindy Snyder DNP, ACGN, FNP-C. CBCN: Can you request a copy from the lab that performed the test?

01:05:36 Dara McKinley FNP-C AGN-BC: I would make sure she had panel testing--you can also aske the year

01:05:45 Dara McKinley FNP-C AGN-BC: prior to 2015 usually not panel

01:06:00 Bitá Nehoray (she/her): But given the gastric cancers in the family, I would hope it was more than a breast panel

01:06:01 Allison Jay: would you do a skin biopsy since she has lymphoma

01:06:06 Christina Rybak: Yes you want documentation that she has had multigene panel testing

01:06:35 Erica Kessler: I've had patients who think they had testing but it was really tumor testing

01:06:38 Christina Rybak: And her MSI/MSS status is relevant

01:06:40 Christine Strub: Sometimes patients say they had genetic testing but it was just MMR-deficiency

01:06:45 karco: if she knows what company - you can reach out to the company and actually - I have asked companies if they tested this patient and then had patient request the results

01:06:46 Christina Rybak: possibly

01:08:04 Dara McKinley FNP-C AGN-BC: "When in doubt punch it out"

01:08:12 Dara McKinley FNP-C AGN-BC: I think that was Dr. Churpek

01:08:58 Michelle Willman: If not tested within our health system, maybe request record release for where she may have been tested/genetics/oncology notes. Is she EPIC for checking careEverywhere records

01:09:28 Jeffrey Weitzel: For those interested in more about Traceback concept (also a thank you to CCGCoP members who participated in survey). Delahunty, R., L. et al., TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. Journal of Clinical Oncology, 2022. 40(18): p. 2036-2047.  
Nehoray, B., et al., Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment. J Genet Couns, 2022.

01:09:33 Bitá Nehoray (she/her): I would put more effort in getting her germline results from 2017 than a skin punch right now

01:09:53 Dara McKinley FNP-C AGN-BC: I agree with Bitá

01:10:08 Elyssa Zukin: I agree as well

01:10:13 Cindy Snyder DNP, ACGN, FNP-C. CBCN: Agree!

01:10:40 Bitá Nehoray (she/her): and/or find out who was treating her at the time of her testing in 2017 and go to them

01:10:57 Bitá Nehoray (she/her): GeneDx may be another

01:11:02 Lauren Gima (she/her): \*for cancer germline testing

01:11:33 Bitá Nehoray (she/her): Correct, Invitae cultured fibroblast testing is on hold until they set up again

01:11:46 Whitney Sanders: Ambry also does fibroblast testing

01:11:59 Lauren Gima (she/her): yes, they partner with Baylor I think

01:12:04 Clinical Cancer Genetics: Reminder: This is our last Working Group session of 2022. The next session will be on January 4th, 2023.

01:12:14 Nancy Posner: They can offer release form by email to pt

01:12:36 Cindy Snyder DNP, ACGN, FNP-C. CBCN: Happy Holidays!

01:12:57 Dara McKinley FNP-C AGN-BC: Thank you all for a great year!! Can't wait to see you in 2023

01:12:58 City of Hope - PopSci Conference Room: Stay tuned for the update conf agenda coming soon!!!!

01:13:07 City of Hope - PopSci Conference Room: 🤗

01:13:19 Bitá Nehoray (she/her): and Gala theme! :D

01:13:25 rkhan019: Happy holidays to everyone! See you soon at the conference!

01:13:33 Dara McKinley FNP-C AGN-BC: yay! Dance party!

01:13:34 COH - John Luna: before next week hopefully

01:13:36 Christina Rybak: woohoo it's gonna be great

01:13:41 Christina Rybak: happy holidays alls